This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NeoStem Appoints Stephen W. Potter As Executive Vice President

NEW YORK, July 22, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, announced today the appointment of Stephen W. Potter as Executive Vice President of the Company. Mr. Potter is a seasoned and successful senior executive with extensive management experience in the biotechnology and pharmaceutical industries.  Stephen has served since February on NeoStem's Board of Directors and its Nominating and Governance Committee.  Upon his appointment as Executive Vice President, Stephen resigned from the Company's Board of Directors.

Stephen Potter
NeoStem Appoints Stephen W. Potter as Executive Vice President.

"Stephen brings a history of success in cell therapy development and global operations and, combined with his existing working knowledge of both the research and operations of our Company, he will be a key figure in our future success," said Dr. Robin L. Smith, Chairman and CEO of NeoStem. "As NeoStem moves forward in growing its contract development and manufacturing services business, continues the development and looks ahead to the commercial launch of its therapeutic product pipeline, and evaluates multiple business development opportunities, we expect Stephen's demonstrated experience to have a significant impact on our Company's value."

"I am excited to join the NeoStem team, working collaboratively with its management and advisors, to drive significant value for the Company," said Mr. Potter. "I believe that cell therapies will play a significant role in the fight against chronic disease. NeoStem has developed a unique platform of contract services as well as developing its own pipeline of cell therapy products and I am pleased to work with Dr. Robin Smith and the Company's top notch team in the building of a world class, highly competitive and profitable business."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs